Page last updated: 2024-09-04

docetaxel anhydrous and Lethargy

docetaxel anhydrous has been researched along with Lethargy in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Barrett-Lee, P; Bartlett, JM; Bliss, JM; Bloomfield, D; Cameron, D; Canney, P; Coleman, R; Dowsett, M; Earl, H; Ellis, I; Ellis, P; Hall, E; Hopwood, P; Johnson, L; Johnston, S; O'Reilly, S; Peckitt, C; Poole, C; Smith, I; Twelves, C; Verrill, M; Wardley, A; Yarnold, J	1

Trials

1 trial(s) available for docetaxel anhydrous and Lethargy

Article	Year
Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. Lancet (London, England), 2009, May-16, Volume: 373, Issue:9676 Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Belgium; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Early Diagnosis; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Lethargy; Leukopenia; Middle Aged; Neutropenia; Proportional Hazards Models; Receptors, Estrogen; Taxoids; Treatment Outcome; United Kingdom	2009

Article

Year

Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial.

Lancet (London, England), 2009, May-16, Volume: 373, Issue:9676

Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Belgium; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Early Diagnosis; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Lethargy; Leukopenia; Middle Aged; Neutropenia; Proportional Hazards Models; Receptors, Estrogen; Taxoids; Treatment Outcome; United Kingdom

2009